Phase 2 Thyroid Cancer Trial, Recruiting NCT06374602 Sponsor: Saint Petersburg State University, Russia Condition: Thyroid Cancer
Back to Thyroid Cancer

Phase 2 Thyroid Cancer Trial, Recruiting

NCT06374602
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with anaplastic thyroid cancer, confirmed by lab testing of a tissue sample, and surgery to fully remove the cancer is not possible
  • You are 18 years of age or older
  • You are reasonably active and able to care for yourself in daily life (this is measured on a standard scale — confirm with trial site)
  • Your heart, liver, kidneys, and blood counts are working well enough to handle treatment
  • You are able to read and sign a consent form agreeing to take part

Who may not be able to join:

  • Your cancer has a specific gene change called BRAF V600 and you have not yet tried targeted treatments known as BRAF/MEK inhibitors for it
  • You are experiencing significant coughing up of blood or serious bleeding, for example from the digestive system or from the tumor itself
  • The tumor has grown into major blood vessels
  • You have open wounds or abnormal passages (called fistulas) in the body
  • You have a medical reason that prevents you from safely taking any of the drugs being studied in this trial
  • Your overall health and activity level is significantly limited (the lower end of the standard scale mentioned above — confirm with trial site)
  • You are currently taking medications that suppress your immune system on an ongoing basis
  • You have previously taken part in a clinical trial involving experimental drugs
  • You are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +7(921)951-70-88

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Saint Petersburg State University, Russia
Registry
ClinicalTrials.gov
Start date
25 March 2024
Est. completion
25 March 2026

Where this trial is recruiting

🇷🇺 Russia

Primary endpoints

Objective response rate; Progression-Free Survival; Safety and Tolerability assessment (Incidence of Treatment-Emergent Adverse Events)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov